Inhibition of hepatitis viral replication by siRNA

Bibliography

• HUGLE T, CERNY A: Current therapy andnew molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med. Virol (2003) 13:361–371.
   PubMed Web of Science ®Google Scholar
• •A summary of drug therapy and molecular approaches at present, such as ribozymes and antisense, for the treatment of HCV infection.
   Google Scholar
• KEEFFE EB, DIETERICH DT, HAN SH et al: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin. Gastroenterol Hepatol (2004) 2:87–106.
   PubMed Web of Science ®Google Scholar
• •A state-of-the-art update of present management of chronic hepatitis B viral infection.
   Google Scholar
• STRADER DB, WRIGHT T,THAMAS DL, SEEFF LB: Diagnosis, management and treatment of hepatitis C. Hepatology (2004) 39:1147–1171.
   PubMed Web of Science ®Google Scholar
• PAPATHEODORIDIS GV,HADZIYANNIS SJ: Current management of chronic hepatitis B. Aliment. Pharmacol The]: (2004) 19:25–37.
   PubMed Web of Science ®Google Scholar
• SCHERER LJ, ROSSI JJ: Approaches for the sequence-specific knockdown of mRNA. Nat. Biotechnol (2003) 21:1457–1465.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive comparison of molecularapproaches available at present for the sequence-specific knockdown of mRNA, implications of their advantages, disadvantages, and their technical key elements.
   Google Scholar
• BENNETT CF, COWSERT LM: Application of antisense oligonucleotides for gene functionalization and target validation. Carr. Opin. MM. Ther. (1999) 1:359–371.
   PubMed Web of Science ®Google Scholar
• ZERN MA, OZAKI I, DUAN LX et al: Novel 5V40-based vector successfully transduces and expresses an al-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther. (1999) 6:114–120.
   PubMed Web of Science ®Google Scholar
• DUAN YY, WU J, ZHU JL et al: Gene therapy for human al-antitrypsin deficiency in an animal model using 5V40-derived vectors. Gastroenterology (2004) (In Press).
   Google Scholar
• MORRISSEY DV, LEE PA,JOHNSON DA et al.: Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA. I Virol Hepatitis (2002) 9:411–418.
   Google Scholar
• SPANGENBERG HC, WANDS JR: Ribozymes and hepatitis B virus. Gastroenterol Hepatol (2001) 16:1084–1085.
   Web of Science ®Google Scholar
• NAKAZONO K, ITO Y, WU CH, WU GY: Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology (1996) 23:1297–1303.
   PubMed Web of Science ®Google Scholar
• SONI PN, BROWN D, SAFFIE R et al.:Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology (1998) 28:1402–1410.
   PubMed Web of Science ®Google Scholar
• FIRE A, XU S, MONTGOMERY MK et al.: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis. Nature (1998) 391:806–811.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, LENDECHEL W, TUSCHI T: RNA interference is mediated by 21- and 22-nucleatide RNAs. Genes Dev. (2001) 15:188–200.
   PubMed Web of Science ®Google Scholar
• DYKXHOORM DM, NOVINA CD, SHARP PA: Killing the messenger: short RNAs that silence gene expression. Nat. Rev Ma Biol. (2003) 4:457–467.
   PubMed Web of Science ®Google Scholar
• ••A state-of-the-art review and in-depthintroduction of the technology of siRNA-mediated sequence-specific gene silencing.
   Google Scholar
• CARMICHAEL G: Silencing viruses with RNA. Nature (2002) 418:379–380.
   PubMed Web of Science ®Google Scholar
• XIA HB, MAO QW, ELIASON S et al: RNAi therapy for dominant neurodegenerative disease. MM. Ther. (2004) 9:S273 (abstract).
   Google Scholar
• HANNON G: RNA interference. Nature (2002) 418:244–250.
   PubMed Web of Science ®Google Scholar
• ••A state-of-the-art introduction of themechanism and applications of RNAi.
   Google Scholar
• XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol (2002) 20:1006–1010.
   PubMed Web of Science ®Google Scholar
• •A successful demonstration of viral vector-mediated RNAi in the treatment of a neurodegenerative disorder, polyglutarnine disease, in an animal model.
   Google Scholar
• NOVINA CD, SHARP PA: The RNAi revolution. Nature (2004) 430:161–164
   PubMed Web of Science ®Google Scholar
• KONISHI M, WU C, WU GY: Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology (2003) 38:842–850.
   PubMed Web of Science ®Google Scholar
• LI MJ, KIM J, ZAIZ J, YEE JK, ROSSI JJ:Development of lentiviral vectors carrying shRNA, ribozyme and RNA decoy for the inhibition of HIV-1 infection. Mol Ther. (2004) 9:S140 (abstract).
   Google Scholar
• WU J, WU GY, ZERN MA: The prospectsof hepatic drug delivery and gene therapy. Expert Opin. Invesug. Drugs. (1998) 7:1795–1817.
   PubMedGoogle Scholar
• BANERJEA A, LI MJ, BAUER G et al: Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Ther. (2003) 8:62–71.
   Google Scholar
• KIM DH, LONGO M, HAN Y et al.: Interferon induction by siRNAs and siRNAs synthesized by phage polymerase. Nat. Biotechnol (2004) 22:321–325.
   PubMed Web of Science ®Google Scholar
• BRIGDE AJ, PEBERNARD S, DUCRAUX A et al.: Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. (2003) 34:263–264.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY A, NAKAI H, PANDEY K et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol (2003) 21:639–644.
   PubMed Web of Science ®Google Scholar
• ••A successful demonstration that siRNAagainst HBV is effective in lowering the viral transcripts, replicons and proteins in an animal model.
   Google Scholar
• SHLOMAI A, SHAUL Y: Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology (2003) 37:764–770.
   PubMed Web of Science ®Google Scholar
• WU J, NANTZ MH, ZERN MA: Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications. Front. Biosci. (2002) 7:d717–d725.
   PubMed Web of Science ®Google Scholar
• LIU L, ZERN MA, LIZARZABURU ME, NANTZ MH, WU J: Poly(cationic mediated in vivo gene delivery to mouse liver. Gene Ther: (2003) 10:180–187.
   PubMed Web of Science ®Google Scholar
• WU J, LIU L, YEN YD et al: Liposome-mediated extracellular superoxide dismutase gene delivery protects against acute liver injury in mice. Hepatology (2004) 40:195–204.
   PubMed Web of Science ®Google Scholar
• REYNOLDS A, LEAKE D, BOESE Q et al: Rational siRNA design for RNA interference. Nat. Biotechnol (2004) 22:326–330.
   PubMed Web of Science ®Google Scholar
• ••A basic study of the rational design ofeffective siRNA and its criteria.
   Google Scholar
• SONG E, LEES, WANG J et al: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. (2003) 9:347–351.
   PubMed Web of Science ®Google Scholar
• WANG Q, NIE Q, FENG Z: RNA interference: antiviral weapon and beyond. Worldj Gastroenterol (2003) 9:1657–1661.
   PubMed Web of Science ®Google Scholar
• BERTRAND J, POTTIER M, VEKRIS A et al.: Comparison of antisense oligonucleotides and siRNAs in cell culture and M vivo. Biochem. Biophys. Res. Commun. (2002) 296:1000–1004.
   PubMed Web of Science ®Google Scholar
• LIANG TJ: The molecular virology of hepatitis B virus: new insights on old virus. In: Postgraduate Course (2000). Update on Viral Hepatitis. The American Association for the Study of Liver Disease (AASLD). (2000):78–82.
   Google Scholar
• BUTH J: A critical role for the chimpanzee model in the study of hepatitis C. Hepatology (2004) 39:1469–1475.
   PubMed Web of Science ®Google Scholar
• KLEIN C, BOCK CT, WEDEMEYER H et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogue and siRNA. Gastroenterology (2003) 125:9–18.
   PubMed Web of Science ®Google Scholar
• ••Another successful study that demonstratesthe effectiveness of siRNA against HBV infection in mice.
   Google Scholar
• GILADI H, KETZINEL GILAD M et al:Small interfering RNA inhibits hepatitis B virus replication in mice. Ma Ther. (2003) 8:769–776.
   PubMed Web of Science ®Google Scholar
• LIU F, SONG Y, LIU D: Hydrodynamic-based transfection in animals by systemic administration of plasmid DNA. Gene Ther: (1999) 6:1258–1266.
   PubMed Web of Science ®Google Scholar
• ROSSMANITH W,CHABICOVSKY M, HERKNER K, SCHULTE-HERMANN R: Cellular gene dose and kinetics of gene expression in mouse livers transfected by high-volume tail-vein injection of naked DNA. DNA Cell Biol. (2002) 21:847–853.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY A, MEUSE L, PHAM T et al.: RNA interference in adult mice. Nature (2002) 418:38–39.
   PubMed Web of Science ®Google Scholar
• PARAN N, COOPER A, SHAUL Y: Interaction of hepatitis B virus with cells. Rev. Med. Virol (2003) 13:137–143.
   PubMed Web of Science ®Google Scholar
• HAMASAKI K, NAKAO K,MATSUMOTO K et al.: Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. (2003) 543:51–54.
   Google Scholar
• YING C, CLERCQ E, NEYTS J: Selective inhibition of hepatitis B virus replication by RNA interference. Biochem. Biophys. Res. Commun. (2003) 309:482–484.
   PubMed Web of Science ®Google Scholar
• BUKH J: The hepatitis C virus. In: Postgraduate Course 2000: Update on Viral Hepatitis. The American Association for theStudy of Liver Disease (AASLD). (2000):102–111.
   Google Scholar
• PENIN F, DUBUISSON J, REY FA et al.:Structural biology of hepatitis C virus. Hepatology (2004) 39:5–19.
   PubMed Web of Science ®Google Scholar
• YOKOTA T, NAOYA S, ENOMOTO N: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBDI. (2003) 4:602–608.
   PubMed Web of Science ®Google Scholar
• KAPADIA SB, BRIDEAU ANDERSEN A,CHISARI FV: Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl. Acad. Sci USA (2003) 100:2014–2018.
   PubMed Web of Science ®Google Scholar
• WILSON JA, JAYASENA S,KHVOROVA A et al: RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. USA (2003) 100:2783–2788.
   PubMed Web of Science ®Google Scholar
• RANDALL G, GANKOUI A, RICE CM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA (2003) 100:235–240.
   PubMed Web of Science ®Google Scholar
• ZHANG J, YAMDA 0, SAKMOTO T et al.: Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular co-factors for hepatitis C virus. Virology(2003) 320:135–143.
   Google Scholar
• MAJUMDER M, STEELE R, GHOSH A et al.: Expression of hepatitis C virus non-structural 5A protein in the liver of transgenic mice. FEBS Lett. (2003) 555:528–532.
   PubMed Web of Science ®Google Scholar
• MERCER DF, SCHILLER DE, ELLIOTT JF et al.: Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. (2001) 7:927–933
   PubMed Web of Science ®Google Scholar
• HSU EC, HIS B,HIROTA-TSUCHIHARA M et al.: Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat. Biotechnol (2003) 21:519–525.
   Google Scholar
• SCHWARZ DS, HUTVAGNER G, DU TT et al.: Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 115:199–208.
   PubMed Web of Science ®Google Scholar
• PADDISON PJ, SILVA JM, CONKLIN DS et al.: A resource for large-scale RNA-interference-based screens in mammals. Nature (2004) 428:427–431.
   PubMed Web of Science ®Google Scholar
• ••The study points to a new directionof RNAi as a novel research tool in its applications.
   Google Scholar